Author

R. Figlin

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.

BACKGROUND The phase 3, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal-cell carcinoma (ccRCC) following anti-PD-(L)1 therapy. At earlier analyses, belzutifan plus lenvatinib significantly improved progre...

D. Heng, M. Schmidinger, R. McDermott et al. · Annals of Oncology · 0 citations

Open access Aug 2026

Operationalizing patient flow in high-complexity service lines: a health system perspective using oncology care

Background Health systems face increasing oncology demand amid workforce constraints and rising care complexity. Outpatient cancer volumes in the United States are projected to grow nearly 18% over the next decade, driven by earlier diagnoses, evolving screening guidelines, and continued site-of-care shifts — while inp...

R. Figlin, Kate O'Shaughnessy, Setu Shah et al. · Frontiers in Health Services · 0 citations